Secondary Refractory
Showing 1 - 25 of >10,000
Relapsed or Refractory B-cell Lymphoma Trial (Relmacabtagene Autoleucel Injection)
Not yet recruiting
- Relapsed or Refractory B-cell Lymphoma
- Relmacabtagene Autoleucel Injection
- (no location specified)
Apr 13, 2023
Adult Patients With Diagnosed Relapsed or Refractory B-cell Lymphoma Who Have Completed Their First Treatment With Regiorense
Recruiting
- Adult Patients With Diagnosed Relapsed or Refractory B-cell Lymphoma Who Have Completed Their First Treatment With Regiorense Injection
- Relmacabtagene Autoleucel Injection
-
Shanghai, Shanghai, ChinaNO.197， Ruijin Er Road
Mar 28, 2023
Primary CNS Lymphoma, Secondary CNS Lymphoma, Relapsed Cancer Trial in Miami (drug, procedure, radiation)
Not yet recruiting
- Primary Central Nervous System Lymphoma
- +3 more
- Pemetrexed
- +3 more
-
Miami, FloridaMiami Cancer Institute at Baptist Health, Inc.
Dec 23, 2022
Primary CNS Lymphoma, Secondary CNS Lymphoma Trial in Beijing (GNC-038)
Recruiting
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
-
Beijing, Beijing, ChinaBeijing Tiantan Hospital, Capital Medical University
Jul 31, 2022
Depression Trial in Halifax (Intensive Short-term Dynamic Psychotherapy, Secondary Care Treatment as Usual)
Completed
- Depression
- Intensive Short-term Dynamic Psychotherapy
- Secondary Care Treatment as Usual
-
Halifax, Nova Scotia, CanadaCapital District Health Authority
Aug 12, 2022
CNS Lymphoma Trial in Chapel Hill, Winston-Salem (Acalabrutinib, Isavuconazole)
Recruiting
- Central Nervous System Lymphoma
-
Chapel Hill, North Carolina
- +1 more
Mar 24, 2022
Acute Myeloid Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Anti-CD33 CAR
Not yet recruiting
- Acute Myeloid Leukemia
- +3 more
- Anti-CD33 CAR T-cells
- Lymphodepletion Therapy
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 3, 2023
Effect of Drug, Toxicity, Drug, Secondary Resistance Trial in Beijing (Apatinib Mesylate, ifosfamide and etoposide)
Completed
- Effect of Drug
- +2 more
- Apatinib Mesylate
- ifosfamide and etoposide
-
Beijing, Beijing, ChinaPeking University People's Hospital
Mar 12, 2022
Previously Treated Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia With
Active, not recruiting
- Previously Treated Myelodysplastic Syndrome
- +7 more
- Decitabine
- Ipilimumab
-
Duarte, California
- +10 more
Jul 2, 2022
Leukemia, MDS, Childhood Acute Myeloid Leukemia in Remission Trial in Minneapolis (biological, drug, procedure)
Recruiting
- Leukemia
- +12 more
- filgrastim
- +6 more
-
Minneapolis, MinnesotaMasonic Cancer Center, University of Minnesota
Jan 20, 2022
Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Recruiting
- Acute Bilineal Leukemia
- +8 more
- Azacitidine
- +3 more
-
Houston, TexasM D Anderson Cancer Center
Jan 24, 2023
Acute Ischemic Stroke Trial in France (Intracranial stenting, Optimal medical care, without additional endovascular procedures)
Not yet recruiting
- Acute Ischemic Stroke
- Intracranial stenting
- Optimal medical care, without additional endovascular procedures
-
Amiens, France
- +21 more
Oct 2, 2023
Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome Trial in United
Completed
- Chronic Myelomonocytic Leukemia
- +4 more
-
Los Angeles, California
- +4 more
Oct 5, 2022
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia Trial in Duarte (Decitabine,
Active, not recruiting
- Acute Myeloid Leukemia
- +5 more
- Decitabine
- +3 more
-
Duarte, CaliforniaCity of Hope Medical Center
Jan 4, 2023
Secondary Prognostic Index in RefrActory Lymphoma
Recruiting
- Diffuse Large B Cell Lymphoma
- Refractory Diffuse Large B-Cell Lymphoma
- prognostic assessment
-
Le Mans, France
- +1 more
Mar 18, 2021
PCNSL, Secondary CNS Lymphoma Trial in Beijing, Guangzhou, Shanghai (ICP-022)
Recruiting
- PCNSL
- Secondary Central Nervous System Lymphoma
-
Beijing, Beijing, China
- +4 more
Jul 28, 2021
Primary CNS Lymphoma, Secondary CNS Lymphoma Trial (F520)
Not yet recruiting
- Primary Central Nervous System Lymphoma
- Secondary Central Nervous System Lymphoma
- (no location specified)
Oct 19, 2020
MDS, de Novo, MDS, Secondary, MDS, Previously Treated Trial in Boston (Venetoclax, Azacitidine, Cytarabine)
Recruiting
- Myelodysplastic Syndromes, de Novo
- +10 more
- Venetoclax
- +10 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 23, 2023
Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute Trial in United States (CYNK-001)
Recruiting
- Leukemia
- +19 more
- CYNK-001
-
Denver, Colorado
- +9 more
Sep 9, 2022
Adult Acute Myeloid Leukemia in Remission, Acute Biphenotypic Leukemia, Early Relapse of Acute Myeloid Leukemia Trial in Duarte
Active, not recruiting
- Adult Acute Myeloid Leukemia in Remission
- +12 more
- cyclophosphamide
- +4 more
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 17, 2022
Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells,
Terminated
- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- +10 more
- Cytarabine
- +3 more
-
Los Angeles, CaliforniaUSC / Norris Comprehensive Cancer Center
Nov 17, 2021
Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome Trial in
Completed
- Myelodysplastic Syndrome
- +4 more
-
Sacramento, CaliforniaUniversity of California Davis Comprehensive Cancer Center
Oct 11, 2021